That's my question too. We don't know what goes on between the FDA and Jay et al. It's possible they discouraged him from applying because the sample size is still too small. I can't think of any other reason not to reapply, unless the FDA is still inclined against Leron. Nader hangover, maybe, or the corruption we saw in the in-house emails during the Covid era. But the most likely is the sample size.